Biotech Company Reduces Workforce Following Failed Cancer Drug Partnership
Foghorn Therapeutics ended its oncology collaboration with Eli Lilly after clinical trial data showed their SMARCA2-targeting cancer candidate did not achieve sufficient efficacy to warrant continued development. The termination of the partnership will result in approximately 40% workforce reduction, leaving the company with 65 employees as it redirects focus to internal pipeline programs. Foghorn's stock price dropped over 40% following the announcement of the failed collaboration.
The partnership between Foghorn and Eli Lilly's Loxo Oncology represented a significant financial commitment, with the pharmaceutical giant investing $380 million total since 2021 to support development of multiple oncology candidates. The failed clinical trial centered on FHD-909, a compound designed to target SMARCA2, a protein involved in cancer cell growth. Despite achieving the desired safety profile and drug exposure levels in early testing, the compound did not demonstrate sufficient therapeutic benefit in patients to justify advancing to the next phase.
With reduced staffing, Foghorn plans to redirect remaining resources toward four alternative programs in development, betting that these candidates may succeed where the Lilly collaboration faltered. The company's financial projections suggest current cash reserves will sustain operations through mid-2029, providing a window for its redirected research efforts to generate promising results.
This development illustrates the inherent risks in cancer drug development, where promising laboratory results and early safety data do not always translate to clinical effectiveness in patients. The layoffs may affect skilled researchers and support staff in the Boston area while also signaling to investors the challenges in oncology research. For patients awaiting new treatment options, the failed program represents a delayed path to potentially beneficial therapies, though Foghorn's pivot to alternative targets could eventually yield viable cancer treatments through different mechanisms.